Sixfold Bioscience, a biotechnology company focused on the development of drug delivery systems for gene therapeutics, has been awarded a third grant through the ‘Analysis for Innovators’ (A4I) programme co-funded by the UK’s innovation agency — Innovate UK. The project will expand the capabilities of Sixfold’s proprietary delivery systems.

Sixfold’s CEO, Dr Zuzanna Brzosko, says:

“We are thrilled to have the opportunity to continue our collaborative efforts with the fantastic research teams at the UK’s National Metrology Institute, The National Physical Laboratory (NPL) Management Ltd, and the National Measurement Laboratory (NML), hosted at LGC. We have made great progress working together on our two previous collaborative projects and look forward to making this new collaboration as successful despite the challenging environment given the current pandemic”

NPL and NML are part of the UK National Measurement System, delivering world-class measurement science and technology and providing traceable and increasingly accurate standards of measurement. Their expertise includes high quality measurement research using a range of approaches to improve the safety and efficacy of advanced therapeutics. The Innovate UK funded collaboration, which officially started on the 1st March 2020, enables Sixfold to access their state-of-the-art technologies, facilities and expertise.

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company based at the Innovation and Translation Hub in White City, London. Sixfold develops nucleic acid-based drug delivery systems, with a current focus on Cell & Gene therapeutics such as short interfering RNA for gene silencing and messenger RNA for gene expression.